CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Price, Forecast & Analysis
TSX:CPH • CA17253X1050
CPH.CA Key Statistics, Chart & Performance
The current stock price of CPH.CA is 14.2 CAD. In the past month the price decreased by -8.62%. In the past year, price increased by 10.16%.
CPH.CA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CPH.CA. When comparing the yearly performance of all stocks, CPH.CA turns out to be only a medium performer in the overall market: it outperformed 50.16% of all stocks.
CPH.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to CPH.CA. CPH.CA has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
CPH.CA Financial Highlights
Over the last trailing twelve months CPH.CA reported a non-GAAP Earnings per Share(EPS) of 0.9. The EPS increased by 4.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 34.68% | ||
| ROA | 11.77% | ||
| ROE | 15.23% | ||
| Debt/Equity | 0.12 |
CPH.CA Forecast & Estimates
7 analysts have analysed CPH.CA and the average price target is 19.58 CAD. This implies a price increase of 37.92% is expected in the next year compared to the current price of 14.2.
For the next year, analysts expect an EPS growth of 52.6% and a revenue growth 50.96% for CPH.CA
CPH.CA Ownership
CPH.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| BHC | BAUSCH HEALTH COS INC | 1.37 | 3.063B | ||
| GSD | DEVONIAN HEALTH GROUP INC | N/A | 1.975B | ||
| CRON | CRONOS GROUP INC | 36.35 | 1.363B | ||
| TLRY | TILRAY BRANDS INC | N/A | 1.203B | ||
| DHT-UN | DRI HEALTHCARE TRUST | 6.9 | 872.942M | ||
| GUD | KNIGHT THERAPEUTICS INC | 124.44 | 585.811M | ||
| WEED | CANOPY GROWTH CORP | N/A | 534.267M | ||
| NGEN | NERVGEN PHARMA CORP | N/A | 408.258M | ||
| TSND | TERRASCEND CORP | N/A | 313.013M |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find more growth stocks the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About CPH.CA
Company Profile
Cipher Pharmaceuticals, Inc. engages in a diversified portfolio of commercial and early to late-stage products. The company is headquartered in Mississauga, Ontario and currently employs 61 full-time employees. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. The company delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
Company Info
CIPHER PHARMACEUTICALS INC
5750 Explorer Drive,, Suite 404
Mississauga ONTARIO L6H 0M2 CA
CEO: Craig Mull
Employees: 5
Phone: 19056025840
CIPHER PHARMACEUTICALS INC / CPH.CA FAQ
What does CIPHER PHARMACEUTICALS INC do?
Cipher Pharmaceuticals, Inc. engages in a diversified portfolio of commercial and early to late-stage products. The company is headquartered in Mississauga, Ontario and currently employs 61 full-time employees. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. The company delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
What is the current price of CPH stock?
The current stock price of CPH.CA is 14.2 CAD. The price decreased by -0.14% in the last trading session.
Does CPH stock pay dividends?
CPH.CA does not pay a dividend.
What is the ChartMill rating of CIPHER PHARMACEUTICALS INC stock?
CPH.CA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Can you provide the growth outlook for CIPHER PHARMACEUTICALS INC?
The Revenue of CIPHER PHARMACEUTICALS INC (CPH.CA) is expected to grow by 50.96% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of CPH stock?
CIPHER PHARMACEUTICALS INC (CPH.CA) has a market capitalization of 360.25M CAD. This makes CPH.CA a Small Cap stock.